Ionis Pharmaceuticals

+$1.54 (+5.11%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.

CEO

Brett P. Monia

Employees

757

Headquarters

Carlsbad, California

Founded

1989

IONS Key Statistics

Market cap

Price-Earnings ratio

—

Dividend yield

—

Average volume

1.49M

High today

$31.70

Low today

$29.87

Open price

$30.04

Volume

827.44K

52 Week high

$62.65

52 Week low

$25.04

IONS News

MarketWatchJan 24

Ionis, AstraZeneca Get FDA Orphan Designation for Eplontersen

By Colin Kellaher Ionis Pharmaceuticals Inc. and AstraZeneca PLC on Monday said the U.S. Food and Drug Administration granted orphan-drug designation to their

Analyst ratings

Buy

52.4%

Hold

33.3%

Sell

14.3%

IONS Earnings

-$0.58

-$0.12

$0.35

$0.81

Q2 FY20

Q3 FY20

Q4 FY20

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Estimated

— per share

Actual

Expected Feb 23, Pre-Market

Why Robinhood?

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. View more

Ionis, AstraZeneca Get FDA Orphan Designation for Eplontersen

52%

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.